Emergency stroke treatment with BXOS110 within 3 hours
Part of Brain & nervous system clinical trials.
This trial tests whether BXOS110, an experimental injection, can help people recover better after an acute ischemic stroke (a stroke caused by a blood clot) when given within 3 hours of symptom onset. The study compares BXOS110 to a placebo to see if it reduces disability and improves recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–85 years old
- Diagnosed with acute ischemic stroke (blood clot stroke) confirmed by imaging
- Stroke symptoms started within the last 3 hours and treatment can begin within 3 hours
- Moderate stroke severity: NIHSS score between 8–25, with some arm or leg weakness
- First stroke, or previous stroke with good recovery (minimal or no lasting disability)
- Blood pressure, blood sugar, and heart rate within safe ranges, no severe heart problems in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests an investigational injection called KPCXM18 for people having an acute ischemic stroke. It is given within 12 hours of symptom onset, in addition to standard clot-dissolving treatment, to see if it improves recovery and safety.
This trial tests an investigational drug, QHRD106, given as an injection for people who have had a moderate-to-severe acute ischemic stroke. It aims to see if the drug can help recovery when given within 24 hours after the stroke starts, and it is for patients who are not receiving standard clot-busting treatment.
This trial tests an investigational drug called B2065 for people who have had a recent ischemic stroke (a stroke caused by a blockage in a blood vessel in the brain). The goal is to see if it is safe and if it might help improve recovery when given within 36 hours of stroke symptoms starting.
This trial tests a new approach to restore blood flow in the brain after a stroke. It aims to improve recovery and brain function in people with a blocked large artery.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
Hear when a new AIS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.